Merck Reports Phase 2b Data for Rucaparib in Hepatocellular carcinoma

Merck today announced Phase 2b results for rucaparib in patients with hepatocellular carcinoma. The study demonstrated that rucaparib achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of hepatocellular carcinoma and support the continued development of rucaparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.